EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudiePragmatische StudieOpen Access · CC BY 4.0

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer

Sharon F McGee, Mark Clemons iD, Gregory Pond iD, Jean-Michel Caudrelier, Michelle Liu, Mashari Jemaan Alzahrani iD, Terry L Ng iD, Arif A Awan, Sandeep Sehdev iD, John Hilton, Marie-France Savard iD, Lesley Fallowfield und 5 weitere

Current Oncology · 07.08.2024 · 31 (8) · 4531-4545

DOI: 10.3390/curroncol31080338 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Current Oncology, online erschienen am 07.08.2024. Verfasst von Sharon F McGee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rethinking Clinical Trials Program (REaCT), Ottawa Hospital Foundation and its generous donors, Canadian Cancer Clinical Trials Network (3CTN).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Concerns exist regarding increased toxicities, including endocrine therapy toxicity, with concurrent radiation and endocrine therapy in early breast cancer (EBC). We present a pragmatic, randomized trial comparing concurrent versus sequential endocrine and radiotherapy in hormone-responsive EBC. In this multicenter trial, patients were randomized to receive adjuvant endocrine therapy concurrent with, or sequential to, radiotherapy. The primary outcome was change in endocrine therapy toxicity from baseline to 3 months post radiotherapy using the Functional Assessment of Cancer Therapy–Endocrine Symptom (FACT-ES) score. From September 2019 to January 2021, 133 patients were randomized to concurrent endocrine and radiotherapy, and 127 to sequential treatment. Most patients were post-menopausal (72.7%, 189/260) with stage 1 disease (65.8%, 171/260). Tamoxifen was the endocrine therapy of choice for 69.6% (181/260) of patients, and an aromatase inhibitor for the remainder. The median total radiation dose and fractions were 40.1 Gray (range 26–50) and 15 fractions (range 5–25), respectively. For the primary outcome of change in endocrine therapy toxicity per FACT-ES scores from baseline to 3 months post radiotherapy, no significant difference was found between the groups (median [range] = −4.9 (−82, 38.8) for concurrent and −5.1 (−42, 40) for sequential, p = 0.87). This is the first trial to investigate the impact of concurrent versus sequential adjuvant endocrine and radiotherapy on endocrine therapy-related toxicities. The findings provide further support to allow the optimal timing of radiation and endocrine therapy to be tailored for the individual patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Agents, HormonalHumansFemaleMiddle AgedAgedAdultTamoxifenAged, 80 and overAromatase InhibitorsNeoplasm Staging

Stichwörter der Autor:innen

breast cancerendocrine therapyquality of liferadiotherapytoxicitytreatment sequence

Substanzen

Antineoplastic Agents, HormonalTamoxifenAromatase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
  • Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
  • SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton BN1 9RH, UK.
  • Markham Stouffville Hospital, Markham, ON L3P 7P3, Canada.
  • Lakeridge Health, Oshawa, ON L1G 8A2, Canada.

ORCID-Profile: Mark Clemons, Gregory Pond, Mashari Jemaan Alzahrani, Terry L Ng, Sandeep Sehdev, Marie-France Savard, Brian Hutton, Jean-Marc Bourque

Förderung

  • Rethinking Clinical Trials Program (REaCT)
  • Ottawa Hospital Foundation and its generous donors
  • Canadian Cancer Clinical Trials Network (3CTN)

Zitieren

APA

McGee, S. F., Clemons, M., Pond, G., Caudrelier, J. M., Liu, M., Alzahrani, M. J., Ng, T. L., Awan, A. A., Sehdev, S., Hilton, J., Savard, M. F., Fallowfield, L., Kumar, V., Freedman, O., Vandermeer, L., Hutton, B., & Bourque, J. M. (2024). A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current Oncology, 31(8), 4531-4545. https://doi.org/10.3390/curroncol31080338

Vancouver

McGee SF, Clemons M, Pond G, Caudrelier JM, Liu M, Alzahrani MJ, et al. A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. Current Oncology. 2024;31(8):4531-4545. doi:10.3390/curroncol31080338

BibTeX
@article{McGee2024,
  author = {McGee, Sharon F and Clemons, Mark and Pond, Gregory and Caudrelier, Jean-Michel and Liu, Michelle and Alzahrani, Mashari Jemaan and Ng, Terry L and Awan, Arif A and Sehdev, Sandeep and Hilton, John and Savard, Marie-France and Fallowfield, Lesley and Kumar, Vikaash and Freedman, Orit and Vandermeer, Lisa and Hutton, Brian and Bourque, Jean-Marc},
  title = {A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer},
  journal = {Current Oncology},
  year = {2024},
  volume = {31},
  number = {8},
  pages = {4531--4545},
  doi = {10.3390/curroncol31080338}
}
Kostenlos starten →